• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods.体积 MRI 分析 1 型神经纤维瘤病中的丛状神经纤维瘤:两种方法的比较。
Acad Radiol. 2018 Feb;25(2):144-152. doi: 10.1016/j.acra.2017.09.004. Epub 2017 Oct 31.
2
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.通过容积磁共振成像测量1型神经纤维瘤病丛状神经纤维瘤的生长速率:与年龄和体重的关系
Neurology. 2007 Feb 27;68(9):643-7. doi: 10.1212/01.wnl.0000250332.89420.e6. Epub 2007 Jan 10.
3
Whole-body MRI-based long-term evaluation of pediatric NF1 patients without initial tumor burden with evidence of newly developed peripheral nerve sheath tumors.基于全身 MRI 的无初始肿瘤负荷且有新发生外周神经鞘瘤证据的儿童 NF1 患者的长期评估。
Orphanet J Rare Dis. 2024 Nov 4;19(1):412. doi: 10.1186/s13023-024-03420-6.
4
18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).18-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)评估 1 型神经纤维瘤病患者结节性病变伴丛状神经纤维瘤(PN)或恶性外周神经鞘瘤(MPNST)。
Pediatr Blood Cancer. 2013 Jan;60(1):59-64. doi: 10.1002/pbc.24212. Epub 2012 May 29.
5
Tumor burden evaluation in NF1 patients with plexiform neurofibromas in daily clinical practice.日常临床实践中对患有丛状神经纤维瘤的1型神经纤维瘤病(NF1)患者的肿瘤负荷评估。
Acta Neurochir (Wien). 2015 May;157(5):855-61. doi: 10.1007/s00701-015-2366-z. Epub 2015 Mar 14.
6
Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions.1 型神经纤维瘤病外周神经鞘瘤的纵向评估:丛状神经纤维瘤和明显结节性病变的生长分析。
Neuro Oncol. 2020 Sep 29;22(9):1368-1378. doi: 10.1093/neuonc/noaa053.
7
The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.妊娠对 1 型神经纤维瘤病中神经纤维瘤生长动力学的影响。
PLoS One. 2020 Apr 28;15(4):e0232031. doi: 10.1371/journal.pone.0232031. eCollection 2020.
8
PNist: interactive volumetric measurements of plexiform neurofibromas in MRI scans.PNist:磁共振成像扫描中丛状神经纤维瘤的交互式容积测量
Int J Comput Assist Radiol Surg. 2014 Jul;9(4):683-93. doi: 10.1007/s11548-013-0961-0. Epub 2013 Nov 20.
9
Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging.利用磁共振成像对1型神经纤维瘤病中的丛状神经纤维瘤进行自动检测和体积测量。
Comput Med Imaging Graph. 2004 Jul;28(5):257-65. doi: 10.1016/j.compmedimag.2004.03.002.
10
[18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.[18F]-氟代脱氧葡萄糖正电子发射断层扫描在 1 型神经纤维瘤病和丛状神经纤维瘤患儿中的应用:与恶性转化的相关性。
J Neurooncol. 2012 Jul;108(3):469-75. doi: 10.1007/s11060-012-0840-5. Epub 2012 Mar 11.

引用本文的文献

1
Identification of the Determinants of Plexiform Neurofibroma Morbidity in Pediatric and Young Adult Neurofibromatosis Type 1 Patients: A Pilot Multivariate Approach.1型神经纤维瘤病患儿和年轻成人丛状神经纤维瘤发病因素的确定:一项探索性多变量研究方法
Cancers (Basel). 2025 Jan 2;17(1):123. doi: 10.3390/cancers17010123.
2
Tumor volume features predict survival outcomes for patients diagnosed with diffuse intrinsic pontine glioma.肿瘤体积特征可预测弥漫性脑桥内在型胶质瘤患者的生存结果。
Neurooncol Adv. 2024 Aug 30;6(1):vdae151. doi: 10.1093/noajnl/vdae151. eCollection 2024 Jan-Dec.
3
Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations.阿拉伯海湾合作委员会地区1型神经纤维瘤病的诊断与管理:挑战与建议
Front Oncol. 2024 Aug 27;14:1323176. doi: 10.3389/fonc.2024.1323176. eCollection 2024.
4
Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.基于平均磁共振成像强度阈值化的半自动分割技术用于丛状神经纤维瘤体积定量分析的开发
Heliyon. 2023 Dec 9;10(1):e23445. doi: 10.1016/j.heliyon.2023.e23445. eCollection 2024 Jan 15.
5
Developing Semiautomated Methods to Measure Pre- and Postoperative Syrinx Volumes.开发半自动方法测量术前和术后脊髓空洞体积。
J Clin Med. 2023 Oct 24;12(21):6725. doi: 10.3390/jcm12216725.
6
Clinical Characteristics and Management of Children and Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Denmark: A Nationwide Study.丹麦1型神经纤维瘤病合并丛状神经纤维瘤儿童及成人的临床特征与管理:一项全国性研究
Oncol Ther. 2023 Mar;11(1):97-110. doi: 10.1007/s40487-022-00213-4. Epub 2022 Dec 1.
7
Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and Meta-Analysis.曲美替尼治疗1型神经纤维瘤病相关丛状神经纤维瘤和低级别胶质瘤的疗效与安全性:一项系统评价和荟萃分析
Pharmaceuticals (Basel). 2022 Jul 31;15(8):956. doi: 10.3390/ph15080956.
8
[Progress in diagnosis and treatment of neurofibromatosis in children].[儿童神经纤维瘤病的诊断与治疗进展]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Jun;36(6):477-482. doi: 10.13201/j.issn.2096-7993.2022.06.015.
9
Management of neurofibromatosis type 1-associated plexiform neurofibromas.1 型神经纤维瘤病相关丛状神经纤维瘤的治疗管理。
Neuro Oncol. 2022 Nov 2;24(11):1827-1844. doi: 10.1093/neuonc/noac146.
10
DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.DINs:基于全身 MRI 的 1 型神经纤维瘤病中神经纤维瘤分割的深度交互式网络。
IEEE J Biomed Health Inform. 2022 Feb;26(2):786-797. doi: 10.1109/JBHI.2021.3087735. Epub 2022 Feb 4.

本文引用的文献

1
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.司美替尼在1型神经纤维瘤病相关丛状神经纤维瘤中的活性
N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943.
2
Observer variability in RECIST-based tumour burden measurements: a meta-analysis.基于RECIST的肿瘤负荷测量中的观察者变异性:一项荟萃分析。
Eur J Cancer. 2016 Jan;53:5-15. doi: 10.1016/j.ejca.2015.10.014. Epub 2015 Dec 10.
3
Approximation of head and neck cancer volumes in contrast enhanced CT.在增强CT中对头颈部癌体积的估算
Cancer Imaging. 2015 Sep 29;15:16. doi: 10.1186/s40644-015-0051-3.
4
Inter-Method Performance Study of Tumor Volumetry Assessment on Computed Tomography Test-Retest Data.基于计算机断层扫描重测数据的肿瘤体积评估方法间性能研究
Acad Radiol. 2015 Nov;22(11):1393-408. doi: 10.1016/j.acra.2015.08.007. Epub 2015 Sep 14.
5
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.西罗莫司治疗进展性1型神经纤维瘤病相关丛状神经纤维瘤:神经纤维瘤病临床试验联盟II期研究
Neuro Oncol. 2015 Apr;17(4):596-603. doi: 10.1093/neuonc/nou235. Epub 2014 Oct 14.
6
Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.西罗莫司治疗非进展性 NF1 相关丛状神经纤维瘤:NF 临床试验联盟的 II 期研究。
Pediatr Blood Cancer. 2014 Jun;61(6):982-6. doi: 10.1002/pbc.24873.
7
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.吡非尼酮用于1型神经纤维瘤病和进行性丛状神经纤维瘤儿童及青年的II期试验。
Pediatr Blood Cancer. 2014 Sep;61(9):1598-602. doi: 10.1002/pbc.25041. Epub 2014 Apr 22.
8
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.法尼基转移酶抑制剂替匹法尼用于1型神经纤维瘤病和进行性丛状神经纤维瘤儿童及青年患者的2期随机、灵活交叉、双盲、安慰剂对照试验。
Neuro Oncol. 2014 May;16(5):707-18. doi: 10.1093/neuonc/nou004. Epub 2014 Feb 4.
9
Recommendations for imaging tumor response in neurofibromatosis clinical trials.神经纤维瘤病临床试验中肿瘤反应的影像学推荐建议。
Neurology. 2013 Nov 19;81(21 Suppl 1):S33-40. doi: 10.1212/01.wnl.0000435744.57038.af.
10
Achieving consensus for clinical trials: the REiNS International Collaboration.达成临床试验共识:REiNS 国际合作。
Neurology. 2013 Nov 19;81(21 Suppl 1):S1-5. doi: 10.1212/01.wnl.0000435743.49414.b6.

体积 MRI 分析 1 型神经纤维瘤病中的丛状神经纤维瘤:两种方法的比较。

Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods.

机构信息

3D Imaging Service, Massachusetts General Hospital, Boston, Massachusetts.

Center for Cancer Research, Biostatistics and Data Management Section, National Cancer Institute, Rockville, Maryland.

出版信息

Acad Radiol. 2018 Feb;25(2):144-152. doi: 10.1016/j.acra.2017.09.004. Epub 2017 Oct 31.

DOI:10.1016/j.acra.2017.09.004
PMID:29097016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5794522/
Abstract

OBJECTIVES

Plexiform neurofibromas (PNs) are complex, histologically benign peripheral nerve sheath tumors that are challenging to measure by simple line measurements. Computer-aided volumetric segmentation of PN has become the recommended method to assess response in clinical trials directed at PN. Different methods for volumetric analysis of PN have been developed. The goal of this study is to test the level of agreement in volume measurements and in interval changes using two separate methods of volumetric magnetic resonance imaging analysis.

METHODS

Three independent volume measurements were performed on 15 PN imaged at three time-points using 3DQI software at Massachusetts General Hospital (MGH) and National Cancer Institute (NCI) and MEDx software at NCI.

RESULTS

Median volume differences at each time-point comparing MGH-3DQI and NCI-3DQI were -0.5, -4.2, and -19.9 mL; comparing NCI-3DQI and NCI-MEDx were -21.0, -47.0, and -21.0 mL; comparing MGH-3DQI and NCI-MEDx were -10.0, -70.3, and -29.9 mL. Median differences in percentage change over time comparing MGH-3DQI and NCI-3DQI were -1.7, 1.1, and -1.0%; comparing NCI-3DQI and NCI-MEDx were -2.3, 3.3, and -1.1%; comparing MGH-3DQI and NCI-MEDx were -0.4, 2.0, and -1.5%. Volume differences were <20% of the mean of the two measurements in 117 of 135 comparisons (86.7%). Difference in interval change was <20% in 120 of the 135 comparisons (88.9%), while disease status classification was concordant in 115 of 135 comparisons (85.2%).

CONCLUSIONS

The volumes, interval changes, and progression status classifications were in good agreement. The comparison of two volumetric analysis methods suggests no systematic differences in tumor assessment. A prospective comparison of the two methods is planned.

摘要

目的

丛状神经纤维瘤(PNs)是一种复杂的、组织学良性的周围神经鞘肿瘤,用简单的线测量法很难测量。PN 的计算机辅助容积分割已成为临床试验中评估 PN 反应的推荐方法。已经开发出不同的 PN 容积分析方法。本研究的目的是测试使用两种独立的磁共振成像分析容积方法测量体积和间隔变化的一致性水平。

方法

在马萨诸塞州总医院(MGH)和国家癌症研究所(NCI)使用 3DQI 软件以及在 NCI 使用 MEDx 软件对 15 个 PN 在三个时间点进行了三次独立的体积测量。

结果

比较 MGH-3DQI 和 NCI-3DQI 时,每个时间点的中位体积差异分别为-0.5、-4.2 和-19.9 mL;比较 NCI-3DQI 和 NCI-MEDx 时,分别为-21.0、-47.0 和-21.0 mL;比较 MGH-3DQI 和 NCI-MEDx 时,分别为-10.0、-70.3 和-29.9 mL。比较 MGH-3DQI 和 NCI-3DQI 时,时间百分比变化的中位差异分别为-1.7、1.1 和-1.0%;比较 NCI-3DQI 和 NCI-MEDx 时,分别为-2.3、3.3 和-1.1%;比较 MGH-3DQI 和 NCI-MEDx 时,分别为-0.4、2.0 和-1.5%。在 135 次比较中的 117 次(86.7%),体积差异小于两个测量值平均值的 20%。在 135 次比较中有 120 次(88.9%)的间隔变化差异小于 20%,而在 135 次比较中有 115 次(85.2%)疾病状态分类一致。

结论

体积、间隔变化和进展状态分类具有良好的一致性。两种容积分析方法的比较表明,肿瘤评估没有系统差异。计划对两种方法进行前瞻性比较。